Dr. Cavalier is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
50 Binney St
Cambridge, MA 02142Phone+1 857-202-7146
Summary
- Board certified neurologist with specialty in MS. Practiced for 25 years. For past 8 years have worked in pharma in the area of MS. Currently, head of global MS scientific communications for Sanofi Genzyme.
Education & Training
Cleveland Clinic FoundationResidency, Neurology, 1978 - 1981
Tulane University School of MedicineClass of 1977
Certifications & Licensure
LA State Medical License 1977 - 2013- American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- 13 citationsProportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years.Dana Horakova, Aaron Boster, Antonio Bertolotto, Mark S. Freedman, Isabel Firmino
Multiple Sclerosis Journal - Experimental, Translational and Clinical. 2020-12-18 - 8 citationsSlowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MSRobert Zivadinov, Michael G. Dwyer, Ellen Carl, Elizabeth M. Poole, Steve Cavalier
Therapeutic Advances in Neurological Disorders. 2020-11-11 - 24 citationsPatient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Ter...Patricia K. Coyle, Bhupendra Khatri, Keith R. Edwards, José Meca-Lallana, Steve Cavalier
Multiple Sclerosis and Related Disorders. 2018-11-01
Journal Articles
- Teriflunomide in the TOPIC Study: Effect on Cortical Gray Matter AtrophyZivadinov R, Dwyer MG, Carl E, Thangavelu K, Cavalier S, Bergsland N (Order TBC), The Lancet Neurology, 2/26/2019
- Correlation Between Brain Volume Loss and Long-term Disability Worsening in Patients With MS: SIENA Analysis of TEMSO MRI DataSprenger T, Kappos L, Radue EW, Gaetano L, Mueller-Lenke N, Wuerfel J, Thangavelu K, Cavalier S, Multiple Sclerosis Journal, 1/9/2019
- Rate of conversion from relapsing-remitting MS to secondary progressive MS in patients treated with alemtuzumab: 6-year follow-up of CARE-MS I and IIHorakova D, Boster A, Bertolotto A, Freedman MS, Firmino I, Cavalier SJ, Thangavelu K, Margolin DH, Ziemssen T; on behalf of the CARE-MS I, CARE-MS II, and CAMMS03409 ..., JAMA Neurology, 1/8/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
